Insider trade

CEO sold ~$1.69M of JNJ shares in the open market

Traded Aug 5, 2026 · Filed Aug 7, 2026

Johnson & JohnsonJNJ

~$1.69M
Reported value · 6,523 sh @ $258.739: 276K
Holds after · shares reported: +0.4%
stock since the trade · S&P 500 -0.8%, $257.59 → $258.66 on Oct 1

Why it stands out

The boss of Johnson & Johnson sold $1.69M of Johnson & Johnson shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 5, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 7, 2026

CEO$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$1,687,755

Shares × reported transaction price

Timing vs results

21 days after results of Jul 15, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $257.59 on Aug 5, 2026, within 4% of its 52-week high, after an 8% rise over the previous 30 trading days

52-week range $170.59 (Aug 6, 2025) to $267.24 (Jul 7, 2026), 90% of the way up, from 251 adjusted closes. 30 trading days earlier: $239.08 on Jun 23, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Imaavy on Aug 24, 2026, 19 days after this trade.

New use approved (efficacy supplement). Active ingredient: Nipocalimab-Aahu. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+0.2%	-0.1%	+0.3%
30 days	+2.0%	-1.4%	+3.4%

Past results only. Not a forecast.

Source receipt

Record ID: 0000200406-26-000171
Filed / recorded: Aug 7, 2026, 9:50 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: JOHNSON & JOHNSON
Issuer CIK: 200406
Ticker: JNJ
Reporting person: Joaquin Duato
Relationship: Director, Officer
Officer title: CEO and Chairman of the Board
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Aug 5, 2026
Transaction code: S
Shares / units: 6,523
Price per share: $258.739
Acquired / disposed: Disposed (D)
Shares owned after: 275,967
Ownership form: Direct
Amendment: No

Footnotes from the filing

This transaction was executed in multiple trades at prices ranging from $258.535 to $259.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Around the same time

4w ago

11KShares · @ $131.94

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record

Chair sold4w ago

~$3.04MReported value · 11K sh @ $274.74

Johnson & Johnson's WW Chair, MedTech sold $3.04M of Johnson & Johnson shares. Nobody planned it ahead of time.

Why it stands out Official record

4w ago

23KShares · @ $151.41

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record